Strides’ Teriparatide And Viatris’ Pirfenidone Receive CHMP Nods
While AOP Orphan Pharmaceuticals Gets Positive Opinion For Sugammadex
Executive Summary
Strides Pharma’s biosimilar teriparatide version of Forsteo has been granted a positive opinion by the EMA’s CHMP, setting the firm up for a pan-European marketing authorization along with Viatris’ pirfenidone generic rival to Esbriet and AOP Orphan Pharmaceuticals’ sugammadex generic of Bridion.